Progress and prospects for the use and the understanding of the mode of action of autologous hematopoietic stem cell transplantation in the treatment of multiple sclerosis

References

• Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Publish Group. 2015;15(9):545–558. DOI:10.1038/nri3871
   Web of Science ®Google Scholar
• Dutta R, Trapp BD. Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol. 2011;93(1):1–12. DOI:10.1016/j.pneurobio.2010.09.005
   PubMed Web of Science ®Google Scholar
• Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015). Guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15(4):273–279. DOI:10.1136/practneurol-2015-001139.
   PubMedGoogle Scholar
• Fassas A, Anagnostopoulos A, Kazis A, et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant. 1997;20(8):631–638.
   PubMed Web of Science ®Google Scholar
• Snowden JA, Saccardi R, Allez M, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2012;47(6):770–790. DOI:10.1038/bmt.2011.185
   PubMed Web of Science ®Google Scholar
• Burt RK, Slavin S, Burns WH, et al. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood. 2002;99(3):768–784. DOI:10.1182/blood.V99.3.768
   PubMed Web of Science ®Google Scholar
• Burt RK, Padilla J, Begolka WS, et al. Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis. Blood. 1998;91(7):2609–2616. DOI:10.1111/j.1600-065X.1981.tb00337.x
   PubMed Web of Science ®Google Scholar
• van Bekkum DW. Stem cell transplantation in experimental models of autoimmune disease. J Clin Immunol. 2000;20(1):10–16. DOI:10.1023/A:1006682225181
   PubMed Web of Science ®Google Scholar
• Karussis DM, Vourka-Karussis U, Lehmann D, et al. Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation. J Clin Invest. 1993;92(2):765–772. DOI:10.1172/JCI116648
   PubMed Web of Science ®Google Scholar
• Karussis DM, Slavin S, Ben-Nun A, et al. Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation. J Neuroimmunol. 1992;39(3):201–210. DOI:10.1016/0165-5728(92)90254-I
   PubMed Web of Science ®Google Scholar
• Karussis DM, Slavin S, Lehmann D, et al. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. J Immunol. 1992;148(6):1693–1698.
   PubMed Web of Science ®Google Scholar
• van Gelder M, Kinwel-Bohre EP, van Bekkum DW. Treatment of experimental allergic encephalomyelitis in rats with total body irradiation and syngeneic BMT. Bone Marrow Transplant. 1993;11(3):233–241.
   PubMed Web of Science ®Google Scholar
• Cassiani-Ingoni R, Muraro PA, Magnus T, et al. Disease progression after bone marrow transplantation in a model of multiple sclerosis is associated with chronic microglial and glial progenitor response. J Neuropathol Exp Neurol. 2007;66(7):637–649. DOI:10.1097/nen.0b013e318093f3ef
   PubMed Web of Science ®Google Scholar
• van Gelder M, Van Bekkum DW. Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation. Bone Marrow Transplant. 1996;18(6):1029–1034.
   PubMed Web of Science ®Google Scholar
• van Bekkum DW. Experimental basis of hematopoietic stem cell transplantation for treatment of autoimmune diseases. J Leukoc Biol. 2002;72(4):609–620. DOI:10.1016/S0065-2776(08)60753-1
   PubMed Web of Science ®Google Scholar
• Chan J, Ban EJ, Chun KH, et al. Transplantation of bone marrow transduced to express self-antigen establishes deletional tolerance and permanently remits autoimmune disease. J Immunol. 2008;181(11):7571–7580. DOI:10.4049/jimmunol.181.11.7571
   PubMed Web of Science ®Google Scholar
• Brocker T, Riedinger M, Karjalainen K. Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J Exp Med. 1997;185(3):541–550. DOI:10.1084/jem.185.3.541
   PubMed Web of Science ®Google Scholar
• Mancardi GL, Sormani MP, Gualandi F, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology. 2015;84(10):981–988. DOI:10.1212/WNL.0000000000001329
   PubMed Web of Science ®Google Scholar
• Currò D, Mancardi G. Autologous hematopoietic stem cell transplantation in multiple sclerosis: 20 years of experience. Neurol Sci. 2016;37(6):857–865. DOI:10.1007/s10072-016-2564-3
   PubMed Web of Science ®Google Scholar
• Saccardi R, Freedman M, Sormani M, et al. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. Mult Scler. 2012;18(6):825–834. DOI:10.1177/1352458512438454
   PubMed Web of Science ®Google Scholar
• Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS). JAMA Neurol. 2015;72(2):159–169. DOI:10.1001/jamaneurol.2014.3780
   PubMed Web of Science ®Google Scholar
• Burman J, Iacobaeus E, Svenningsson A, et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatr. 2014;85(10):1116–1121. DOI:10.1136/jnnp-2013-307207
   PubMed Web of Science ®Google Scholar
• Burt RK, Balabanov R, Han X, et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2015;313(3):275–284. DOI:10.1001/jama.2014.17986
   PubMed Web of Science ®Google Scholar
• Sormani MP, Muraro P. Updated views on autologous hematopoietic stem cell transplantation for treatment of multiple sclerosis. Expert Rev Neurother. 2016;16(5):469–470. DOI:10.1586/14737175.2016.1158648
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. The Lancet. 2012;380(9856):1829–1839. DOI:10.1016/S0140-6736(12)61768-1
   PubMed Web of Science ®Google Scholar
• Butzkueven H, Kappos L, Pellegrini F, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational program results. J Neurol Neurosurg Psychiatr. 2014;85(11):jnnp–2013–306936–1197. DOI:10.1136/jnnp-2013-306936
   Web of Science ®Google Scholar
• Atkins HL, Bowman M, Allan D, et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. The Lancet. 2016;388(10044):576–585. DOI:10.1016/S0140-6736(16)30169-6
   PubMed Web of Science ®Google Scholar
• Mancardi G, Sormani M, Di Gioia M, et al. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler. 2012;18(6):835–842. DOI:10.1177/1352458511429320
   PubMed Web of Science ®Google Scholar
• Krasulova E, Trneny M, Kozak T, et al. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult Scler. 2010;16(6):685–693. DOI:10.1177/1352458510364538
   PubMed Web of Science ®Google Scholar
• Fassas A, Kimiskidis VK, Sakellari I, et al. Long-term results of stem cell transplantation for MS: a single-center experience. Neurology. 2011;76(12):1066–1070. DOI:10.1212/WNL.0b013e318211c537
   PubMed Web of Science ®Google Scholar
• Scalfari A, Lederer C, Daumer M, et al. The relationship of age with the clinical phenotype in multiple sclerosis. Mult Scler. 2016;22(13):1750–1758. DOI:10.1177/1352458516630396
   PubMed Web of Science ®Google Scholar
• Burman J, Fransson M, Tötterman TH, et al. T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis. Immunology. 2013;140(2):211–219. DOI:10.1111/imm.12129
   PubMed Web of Science ®Google Scholar
• Fagius J, Lundgren J, Oberg G. Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation. Mult Scler. 2008;15(2):229–237. DOI:10.1177/1352458508096875
   PubMed Web of Science ®Google Scholar
• Chen B, Zhou M, Ouyang J, et al. Long-term efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China. Neurol Sci. 2011;33(4):881–886. DOI:10.1007/s10072-011-0859-y
   PubMed Web of Science ®Google Scholar
• Sousa A, De PA, Malmegrim KCR, et al. Autologous haematopoietic stem cell transplantation reduces abnormalities in the expression of immune genes in multiple sclerosis. Clin Sci. 2015;128(2):111–120. DOI:10.1042/CS20140095
   PubMed Web of Science ®Google Scholar
• Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol. 2011;10(7):649–656. DOI:10.1016/S1474-4422(11)70121-1
   PubMed Web of Science ®Google Scholar
• Samijn JPA, Boekhorst te PAW, Mondria T, et al. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis. J Neurol Neurosurg Psychiatr. 2006;77(1):46–50. DOI:10.1136/jnnp.2005.063883
   PubMed Web of Science ®Google Scholar
• Openshaw H, Lund BT, Kashyap A, et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant. 2000;6(5):563–575. DOI:10.1016/S1083-8791(00)70066-8
   PubMed Web of Science ®Google Scholar
• Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood. 2003;102(7):2364–2372. DOI:10.1182/blood-2002-12-3908
   PubMed Web of Science ®Google Scholar
• Mancardi G, Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol. 2008;7(7):626–636. DOI:10.1016/S1474-4422(08)70138-8
   PubMed Web of Science ®Google Scholar
• Reston JT, Uhl S, Treadwell JR, et al. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. Mult Scler. 2011;17(2):204–213. DOI:10.1177/1352458510383609
   PubMed Web of Science ®Google Scholar
• Hamerschlak N, Rodrigues M, Moraes DA, et al. Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAMsol;horse ATG and CY/rabbit ATG. Bone Marrow Transplant. 2009;45(2):239–248. DOI:10.1038/bmt.2009.127
   PubMed Web of Science ®Google Scholar
• Currò D, Vuolo L, Gualandi F, et al. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: a MRI-based clinical study. Mult Scler. 2015;21(11):1352458514564484. DOI:10.1177/1352458514564484
   Web of Science ®Google Scholar
• Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med. 2005;201(5):805–816. DOI:10.1084/jem.20041679
   PubMed Web of Science ®Google Scholar
• Abrahamsson SV, Angelini DF, Dubinsky AN, et al. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis. Brain. 2013;136(9):2888–2903. DOI:10.1093/brain/awt182
   PubMed Web of Science ®Google Scholar
• Shevchenko JL, Kuznetsov AN, Ionova TI, et al. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis. Exp Hematol. 2012;40(11):892–898. DOI:10.1016/j.exphem.2012.07.003
   PubMed Web of Science ®Google Scholar
• Shevchenko JL, Kuznetsov AN, Ionova TI, et al. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician’s and patient’s perspectives. Ann Hematol. 2015;94(7):1149–1157. DOI:10.1007/s00277-015-2337-8
   PubMed Web of Science ®Google Scholar
• Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica. 2010;95(2):284–292. DOI:10.3324/haematol.2009.013458
   PubMed Web of Science ®Google Scholar
• Wood WA, Krishnamurthy J, Mitin N, et al. Chemotherapy and stem cell transplantation increase p16INK4a expression, a biomarker of T-cell aging. Ebiom. 2016 October 1–12. DOI:10.1016/j.ebiom.2016.08.029
   Web of Science ®Google Scholar
• Arruda LCM, De Azevedo JTC, de Oliveira GLV, et al. Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation. Clin Immunol. 2016;169(C):47–57. DOI:10.1016/j.clim.2016.06.005
   PubMed Web of Science ®Google Scholar
• Darlington PJ, Touil T, Doucet J-S, et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol. 2013;73(3):341–354. DOI:10.1002/ana.23784
   PubMed Web of Science ®Google Scholar
• Arruda LCM, Lorenzi JCC, Sousa APA, et al. Autologous hematopoietic SCT normalizes miR-16, −155 and −142-3p expression in multiple sclerosis patients. Bone Marrow Transplant. 2014 December 1–10. DOI:10.1038/bmt.2014.277
   Web of Science ®Google Scholar
• Muraro PA, Robins H, Malhotra S, et al. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest. 2014;124(3):1168–1172. DOI:10.1172/JCI71691
   PubMed Web of Science ®Google Scholar
• Farge D, Henegar C, Carmagnat M, et al. Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. Arthritis Rheumatol. 2005;52(5):1555–1563. DOI:10.1002/art.21036
   PubMed Web of Science ®Google Scholar
• Alexander T, Thiel A, Rosen O, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood. 2009;113(1):214–223. DOI:10.1182/blood-2008-07-168286
   PubMed Web of Science ®Google Scholar
• Alexander T, Arnold R, Hiepe F, etal. Resetting the immune system with immunoablation and autologous haematopoietic stem cell transplantation in autoimmune diseases. Clin Exp Rheumatol. 2016;34(4):S53–S57.
   Google Scholar
• Venken K, Hellings N, Thewissen M, et al. Compromised CD4+ CD25high regulatory T‐cell function in patients with relapsing‐remitting multiple sclerosis is correlated with a reduced frequency of FOXP3‐positive cells and reduced FOXP3 expression at the single‐cell level. Immunology. 2008;123(1):79–89. DOI:10.1111/j.1365-2567.2007.02690.x
   PubMed Web of Science ®Google Scholar
• Laplaud DA, Ruiz C, Wiertlewski S, et al. Blood T‐cell receptor β chain transcriptome in multiple sclerosis. Characterization of the T cells with altered CDR3 length distribution. Brain. 2004;127(5):981–995. DOI:10.1093/brain/awh119
   PubMed Web of Science ®Google Scholar
• Sun W. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004;127(5):996–1008. DOI:10.1093/brain/awh117
   PubMed Web of Science ®Google Scholar
• Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. Jasn. 2006;17(10):2844–2853. DOI:10.1681/ASN.2006050422
   Web of Science ®Google Scholar
• Autran B, Leblond V, Sadat-Sowti B, et al. A soluble factor released by CD8+CD57+ lymphocytes from bone marrow transplanted patients inhibits cell-mediated cytolysis. Blood. 1991;77(10):2237–2241.
   PubMed Web of Science ®Google Scholar
• Mollet L, Sadat-Sowti B, Duntze J, et al. CD8hi+CD57+ T lymphocytes are enriched in antigen-specific T cells capable of down-modulating cytotoxic activity. Int Immunol. 1998;10(3):311–323.
   PubMed Web of Science ®Google Scholar
• Sadat-Sowti B, Debre P, Mollet L, et al. An inhibitor of cytotoxic functions produced by CD8+CD57+ T lymphocytes from patients suffering from AIDS and immunosuppressed bone marrow recipients. Eur J Immunol. 1994;24(11):2882–2888. DOI:10.1002/eji.1830241145
   PubMed Web of Science ®Google Scholar
• O’Gorman WE, Dooms H, Thorne SH, et al. The initial phase of an immune response functions to activate regulatory T cells. J Immunol. 2009;183(1):332–339. DOI:10.4049/jimmunol.0900691
   PubMed Web of Science ®Google Scholar
• Kebir H, Ifergan I, Alvarez JI, et al. Preferential recruitment of interferon‐γ–expressing TH17 cells in multiple sclerosis. Ann Neurol. 2009;66(3):390–402. DOI:10.1002/ana.21748
   PubMed Web of Science ®Google Scholar
• Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6–regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol. 2009;10(5):514–523. DOI:10.1038/ni.1716
   PubMed Web of Science ®Google Scholar
• Annibali V, Ristori G, Angelini DF, et al. CD161highCD8+T cells bear pathogenetic potential in multiple sclerosis. Brain. 2011;134(2):542–554. DOI:10.1093/brain/awq354
   PubMed Web of Science ®Google Scholar
• Baltimore D, Boldin MP, O’Connell RM, et al. MicroRNAs: new regulators of immune cell development and function. Nat Immunol. 2008;9(8):839–845. DOI:10.1038/ni.f.209
   PubMed Web of Science ®Google Scholar
• Paraboschi EM, Soldà G, Gemmati D, et al. Genetic association and altered gene expression of mir-155 in multiple sclerosis patients. Int J Mol Sci. 2011;12(12):8695–8712. DOI:10.3390/ijms12128695
   PubMed Web of Science ®Google Scholar
• Murugaiyan G, Beynon V, Mittal A, et al. Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J Immunol. 2011;187(5):2213–2221. DOI:10.4049/jimmunol.1003952
   PubMed Web of Science ®Google Scholar
• Waschbisch A, Atiya M, Linker RA, et al. Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. Kleinschnitz C, ed. PloS ONE. 2011;6(9):e24604. DOI:10.1371/journal.pone.0024604
   PubMed Web of Science ®Google Scholar
• Keller A, Leidinger P, Steinmeyer F, et al. Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing. Mult Scler. 2014;20(3):295–303. DOI:10.1177/1352458513496343
   PubMed Web of Science ®Google Scholar
• Feng X, Petraglia AL, Chen M, et al. Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol. 2002;129(1–2):205–215.
   PubMed Web of Science ®Google Scholar
• Liu X, Robinson SN, Setoyama T, et al. FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells. Bone Marrow Transplant. 2014;49(6):793–799. DOI:10.1038/bmt.2014.57
   PubMed Web of Science ®Google Scholar
• Huang B, Zhao J, Lei Z, et al. miR-142-3p restricts cAMP production in CD4+CD25- T cells and CD4+CD25+ TREG cells by targeting AC9 mRNA. EMBO Rep. 2009;10(2):180–185. DOI:10.1038/embor.2008.224
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–1034. DOI:10.1084/jem.192.7.1027
   PubMed Web of Science ®Google Scholar
• Trabattoni D, Saresella M, Pacei M, et al. Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol. 2009;183(8):4984–4993. DOI:10.4049/jimmunol.0901038
   PubMed Web of Science ®Google Scholar
• Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206(13):3015–3029. DOI:10.1084/jem.20090847
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8(3):239–245. DOI:10.1038/ni1443
   PubMed Web of Science ®Google Scholar
• Carter LL, Leach MW, Azoitei ML, et al. PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2007;182(1–2):124–134. DOI:10.1016/j.jneuroim.2006.10.006
   PubMed Web of Science ®Google Scholar
• Zhu B, Guleria I, Khosroshahi A, et al. Differential role of programmed death-ligand 1 and programmed death-ligand 2 in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J Immunol. 2006;176(6):3480–3489.
   Google Scholar
• Salama AD, Chitnis T, Imitola J, et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med. 2003;198(1):71–78. DOI:10.1084/jem.20022119
   PubMed Web of Science ®Google Scholar
• Kroner A, Mehling M, Hemmer B, et al. A PD‐1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol. 2005;58(1):50–57. DOI:10.1002/ana.20514
   PubMed Web of Science ®Google Scholar
• McKinney EF, Lee JC, Jayne DRW, et al. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature. 2015;523(7562):612–616. DOI:10.1038/nature14468
   PubMed Web of Science ®Google Scholar